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Abstract 
Rationale: The tireless research for effective drug delivery approaches is prompted by poor target 
tissue penetration and limited selectivity against diseased cells. To overcome these issues, various nano- 
and micro-carriers have been developed so far, but some of them are characterized by slow degradation 
time, thus hampering repeated drug administrations. The aim of this study was to pursue a selective 
delivery of magnetic biodegradable polyelectrolyte capsules in a mouse breast cancer model, using an 
external magnetic field. 
Methods: Four different kinds of magnetic polyelectrolyte capsules were fabricated via layer-by-layer 
assembly of biodegradable polymers on calcium carbonate templates. Magnetite nanoparticles were 
embedded either into the capsules’ shell (sample S) or both into the shell and the inner volume of the 
capsules (samples CnS, where n is the number of nanoparticle loading cycles). Samples were first 
characterized in terms of their relaxometric and photosedimentometric properties. In vitro magnetic 
resonance imaging (MRI) experiments, carried out on RAW 264.7 cells, allowed the selection of two lead 
samples that proceeded for the in vivo testing on a mouse breast cancer model. In the set of in vivo 
experiments, an external magnet was applied for 1 hour following the intravenous injection of the 
capsules to improve their delivery to tumor, and MRI scans were acquired at different time points post 
administration. 
Results: All samples were considered non-cytotoxic as they provided more than 76% viability of RAW 
264.7 cells upon 2 h incubation. Sample S appeared to be the most efficient in terms of T2-MRI contrast, 
but the less sensitive to external magnet navigation, since no difference in MRI signal with and without the 
magnet was observed. On the other side, sample C6S was efficiently delivered to the tumor tissue, with 
a three-fold T2-MRI contrast enhancement upon the external magnet application. The effective magnetic 
targeting of C6S capsules was also confirmed by the reduction in T2-MRI contrast in spleen if compared 
with the untreated with magnet mice values, and the presence of dense and clustered iron aggregates in 
tumor histology sections even 48 h after the magnetic targeting. 
Conclusion: The highlighted strategy of magnetic biodegradable polyelectrolyte capsules’ design allows 
for the development of an efficient drug delivery system, which through an MRI-guided externally 
controlled navigation may lead to a significant improvement of the anticancer chemotherapy 
performance. 
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The search for effective drug delivery 
approaches is driven by the observation that many 
therapeutic agents failed due to their limited ability to 
reach the target tissue and their poor selectivity 
against diseased cells. Additionally, also the drug 
availability at the pathological site, determined by the 
release of the drug from its carrier, is a critical step. A 
wide variety of carriers have been investigated so far, 
including lipid-based delivery systems [1] and 
conjugates [2], polymeric [3, 4] and inorganic particles 
[5, 6], “host-guest” supramolecular adducts [7, 8], and 
naturally-occurring systems like lipoproteins [9, 10], 
proteins [11, 12], peptides [13, 14], viral capsids 
[15,16], bacteria [17, 18], cells [19,20] and extracellular 
vesicles/exosomes [21]. Drugs can be released from 
the carrier spontaneously or through specific chemical 
(e.g. decreased pH, redox condition, enzymes) or 
physical triggering stimuli (e.g. ultrasound, heat, light, 
electric or magnetic fields) exploited either alone or in 
tandem [22–27]. However, since the amount of drug 
that can be encapsulated is limited and only a small 
percent of carriers reaches the target tissue, the 
efficiency of drug delivery can be controversial. 
Specifically, the analysis of the drug delivery studies 
published in 2005–2015, has shown that only 0.7% 
(median) of the administered nanoparticle dose was 
delivered to a solid tumor [28]. Such a poor efficiency 
is associated with the physiological barriers that a 
drug-carrying platform faces after its intravenous 
injection (for example, diffusion, flow and shear 
forces, aggregation, protein corona adsorption, 
phagocytic sequestration and renal clearance) [29, 30]. 
In terms of cancer treatment, the additional 
limitations are attributed to the heterogeneity of 
tumor vasculature exhibiting the zones of both 
increased and sparse vascular density, hierarchical 
disorganization, serpentine structure and irregular 
branching [28]. In addition to the limited therapeutic 
efficiency, such off-target tissue delivery raises 
toxicity concerns. 
Various targeting strategies enabling a 
site-specific drug addressing have been developed to 
overcome the physiological barriers. Molecular 
systems of all-length scales, from small molecules to 
cells [31, 32], and external physical stimulations, like 
electric and magnetic fields, ultrasound, mechanical 
forces, light and temperature gradients, [33, 34] allow 
the control of the carrier navigation. 
Magnetic targeting has been widely used owing 
to the ability of magnetic fields to penetrate most 
materials [34, 35]. Moreover, magnetic fields can pass 
through the body safely, opening up the perspective 
of magnetic carrier delivery to deep tissues [36]. Both 
static and varying field magnet systems have been 
extensively studied. However, clinical trials mainly 
utilize permanent magnets for magnetic targeting 
[36]. A plenty of magnetic carrier types have been 
proposed and effectively applied for remotely 
controlled targeting purposes [37–40]. Among them, 
magnetic polyelectrolyte multilayer capsules 
represent a unique delivery system allowing for 
remote navigation with magnetic field and in-situ 
release of encapsulated material, including triggered 
drug release in response to physical stimuli, such as 
light or ultrasound [41]. Recently, the enhanced 
delivery effectiveness under external magnet 
application was demonstrated in vitro and in vivo for 
micron- [42, 43] and submicron-sized [44] 
polyelectrolyte multilayer constructs decorated with 
magnetite nanoparticles. 
The monitoring of carrier delivery to a specific 
organ (or tumor in the case of anticancer therapy) is a 
separate challenging task. The doping of carriers by 
magnetite nanoparticles opens opportunities for their 
visualization and control of drug delivery/release 
steps by magnetic resonance imaging (MRI) in vivo 
[44,45]. Moreover, the degradation of a carrier can be 
detected through the change in MRI contrast of 
adjacent tissues caused by the enhancement of 
distance between nanoparticles upon their liberation 
[46]. This also provides an indirect detection of 
encapsulated substance release. Furthermore, initial 
contrast of polyelectrolyte capsules can be controlled 
by the change in their structure or composition [47]. 
By this means, an appropriate structure of such 
capsules can provide the ideal balance between MRI 
contrast and magnetic navigation property while 
keeping the enhanced payload ability. 
Furthermore, the use of drug delivery carriers 
doped with magnetic nanoparticles opens up the 
perspectives for local magnetic hyperthermia of 
adjacent cancer tissues. Since alternating magnetic 
fields enable the heating of magnetic nanoparticles, 
hyperthermia in addition to drug therapeutic effect 
can be granted if particles are localized within the 
tumor [48–50]. Generation of local hyperthermia can 
be exploited also to induce the drug release from the 
delivered carriers [51–53] and to permeabilize the cell 
membranes, with the beneficial consequence of 
improving the drug diffusion in the lesion [54]. 
By this means, fabrication of magnetic 
drug-carrying containers that can provide the 
enhanced drug delivery efficiency together with the 
ability to monitor and prove this delivery is an 
important task in theranostics field, especially in 
anticancer theranostics. The aim of this study was to 
explore the magnetic biodegradable polyelectrolyte 
capsules, combining the externally controlled 




navigation and MRI visualization properties, in vivo in 
a breast cancer mouse model. 
Experimental Section 
Materials 
Calcium chloride (CaCl2), sodium carbonate 
(Na2CO3), ethylene glycol (EG), poly-L-arginine (PA), 
dextran sulfate sodium salt (DS), sodium chloride 
(NaCl), ethylenediaminetetraacetic acid (EDTA), iron 
(III) chloride hexahydrate (FeCl3), iron (II) chloride 
tetrahydrate (FeCl2), potassium ferricyanide, 
hydrochloric acid (HCl) 37%, 10% neutral buffered 
formalin (NBF) and nuclear fast red (NFR) were 
purchased from Sigma-Aldrich (USA). Nitric acid 
(HNO3) 70 % for trace metal analysis was purchased 
from Thermo ScientificTM (USA). Roswell Park 
Memorial Institute Medium (RPMI-1640), Dulbecco's 
Modified Eagle's Medium (DMEM), heat-inactivated 
fetal bovine serum (FBS), L-glutamine, trypsin/EDTA 
and penicillin-streptomycin mixture were purchased 
from Lonza (Belgium). Dulbecco’s phosphate 
buffered saline (PBS), acridine orange (AO) and 
propidium iodide (PI) were purchased from Gibco 
(USA). Bradford Protein Assay was purchased from 
Bio-Rad Laboratories (USA). Milli-Q water was used 
in all experiments (Milli-Q Purification System, 
Millipore, Merck, USA). 
Magnetite synthesis 
The synthesis of magnetite nanoparticles (MNPs) 
was carried out by chemical precipitation from di- 
and trivalent iron salts in the presence of a base. 
Initially, 1.3 g of FeCl3 and 0.48 g of FeCl2 were mixed 
and dissolved in 25 mL of water under room 
temperature, and 0.8 g of citric acid were dissolved in 
water of the same volume. Then, 170 mL of 0.1 M 
NaOH were placed into the reaction cell. To remove 
excessive oxygen, the nitrogen was bubbled through 
the reaction cell, as well as the solutions of iron salts 
and citric acid. The iron salts were injected into the 
reaction cell after its heating until 40 °C with active 
mixing. After this, the obtained suspension was left 
under active mixing and nitrogen pressure for 40 s 
resulting in black sediment formation of magnetite 
nanoparticles. 25 mL of citric acid were further added 
to the reaction cell under constant mixing and 
nitrogen pressure. Dialysis of magnetic hydrosol was 
carried out during 3 days in a 3 L vial under slow 
mixing (50 rpm). 
The size and morphology of the obtained MNPs 
were characterized by means of transmission electron 
microscopy (TEM) using a FEGTEM microscope 
(JEOL, Akishima, Tokyo, Japan) operating at 200 kV. 
For this purpose, a drop of the nanoparticle 
suspension was deposited onto a lacey-carbon copper 
grid. Image analysis and statistics were performed 
using Image J free software. 
The hydrodynamic radius of nanoparticles was 
measured by dynamic light scattering (DLS) using a 
Zetasizer Nano ZS instrument (Malvern Instruments 
Ltd, Malvern, UK). 
Preparation of the carriers 
Magnetic polyelectrolyte capsules were 
fabricated via Layer-by-Layer (LbL) assembly of 
biodegradable polymers on calcium carbonate 
(CaCO3) templates [55]. For this purpose, CaCO3 
submicron particles were synthesized by precipitation 
from the mixture of CaCl2 and Na2CO3 water 
solutions at the EG presence [56]. Equal volumes of 
0.33 M salts were added each to EG in 2:10 volume 
ratio and rapidly stirred at 700 rpm for 3 hours. The 
synthesized CaCO3 particles were thoroughly washed 
twice with water and once with ethanol, afterwards 
they were dried for 30 min at 60°C. 
Two different types of MNP-doped carriers were 
formed then: 1) containing MNPs in the 
polyelectrolyte shell – sample S; 2) containing MNPs in 
both, the shell and the inner volume of the capsules – 
samples CnS. Different CnS samples were obtained 
depending on the amount of incorporated magnetite - 
samples C1S, C2S, C6S. 
To incorporate MNPs into the inner volume of 
the capsules, magnetite nanoparticles were loaded 
into pores of CaCO3 cores before the shell deposition 
via freezing-induced method [57]. For this purpose, 
the weighted portion (40 mg) of dried CaCO3 particles 
was resuspended in 2 mL of 1.7 mg mL-1 MNPs water 
suspension and then kept in a freezing chamber at 
-20 °C for 2 h under slow constant mixing with a 
rotator TetraQuant R-1 (TetraQuant, Russia). After 
that, the samples were thawed at room temperature 
and centrifuged at 3800 g for 1 min to separate the 
particles pellet. Freezing/thawing cycles were 
repeated 1, 2 and 6 times (samples C1S, C2S, C6S, 
respectively). 
In order to incorporate MNPs into the capsules’ 
shell, magnetite nanoparticles were adsorbed from 0.3 
mg mL-1 water suspension as a shell layer. The shells 
were formed by self-assembly method using 
biocompatible PA and DS polyelectrolytes dissolved 
in 0.15 M NaCl at 1 mg mL-1 concentration. For each 
shell layer formation, CaCO3 particles were 
resuspended in 1 mL of the adsorbing solution, and 
the deposition was carried out by continuous shaking 
for 10 minutes. At the end of each adsorption cycle, 
the suspension was centrifuged for 1 minute at 3800 g 
to sediment particles and to remove a supernatant 
liquid phase, and then particles were triply washed 
with water. After consequent deposition of six layers 




(PA/DS/PA/MNPs/PA/DS), CaCO3 templates were 
dissolved in 0.2 M EDTA, and the suspension of 
capsules was triply washed with water, centrifuged at 
3800 g for 3 minutes, and resuspended in water. Thus, 
different hollow MNP-doped biocompatible 
polyelectrolyte submicron capsules were formed 
(samples S, C1S, C2S and C6S). 
Pure six-layered polyelectrolyte submicron 
capsules made of PA and DS were prepared as a 
control. No incorporation of MNPs was made for this 
sample (neither into the shell nor into the inner 
volume of the capsules). 
The morphology of the prepared polyelectrolyte 
capsules was characterized by scanning electron 
microscopy (SEM) using MIRA II LMU instrument 
(Tescan, Czech Republic) at an operating voltage of 20 
kV. Size distribution of the carriers was investigated 
by a set of SEM images in order to obtain a minimum 
of 100 measurements per sample. Image analysis and 
statistics were performed using Image J free software. 
The average size was shown as “mean ± standard 
deviation”. 
The Fe (III) content in magnetic polyelectrolyte 
capsules was determined relaxometrically through 
the glass vial test. For this purpose, aliquots of each 
sample were diluted 1:10 with HNO3 (70% w/w), 
transferred to glass ampoules and centrifuged for 3 
min at 2000 rpm. The glass vials were sealed and 
placed at 120 °C overnight to mineralize the samples. 
Then, the longitudinal relaxation rate (R1obs) was 
measured at 21.5 MHz (0.5 T) and 25 °C using a Stelar 
Spinmaster spectrometer (Stelar srl, Italy). The 
temperature was controlled by a Stelar VTC-91 
airflow heater (Stelar srl, Italy), equipped with a 
copper-constantan thermocouple (uncertainty was ± 
0.1 °C). The millimolar concentration of Fe(III) was 
determined as following: 
[𝐹𝑒3+]= 𝑅1𝑜𝑏𝑠−𝑅1𝑑𝑖𝑎
18.47
× 10 (1) 
where R1dia (R1dia = 0.481 s-1) is the diamagnetic 
contribution in acidic conditions, while 18.47 mM−1 s−1 
is the relaxivity (r1) of the Fe (III) aqua ion in acidic 
conditions at 21.5 MHz and 25 °C (a value determined 
by using standard FeCl3 solutions whose 
concentrations were measured by inductively coupled 
plasma mass spectrometry (ICP-MS), accuracy ± 
0.1 %). 
Relaxivity measurements 
Nuclear magnetic relaxation dispersion (NMRD) 
profiles of the control (pure) polyelectrolyte 
submicron capsules and MNP-doped ones (sample S) 
were recorded at 25 and 37 °C using a Stelar Fast Field 
Cycling FFC2000 NMR relaxometer (Stelar srl, Italy) 
operating at a magnetic field strength ranging from 
0.01 to 20 MHz (2.4x10-4 to 0.47 T). The additional 
points were measured in the range of 20–70 MHz 
(0.47–1.65 T) using a tunable magnet (Stelar srl, Italy). 
The uncertainty of the measurements was lower than 
5%. 
The longitudinal relaxation rates of control 
(pure) polyelectrolyte capsule suspension in water 
measured at various proton Larmor frequencies were 
equal to water. Therefore, the polyelectrolyte shell did 
not affect the relaxivity of MNP-doped capsules and 
their relaxivity changes are caused only by the 
amount and disposition of magnetite nanoparticles in 
their structure. Thus, the normalized (to mM of Fe(III) 
ions) longitudinal relaxivity (r1) of magnetic 






where R1contr is the diamagnetic contribution of pure 
water (R1contr = 0.38 s−1 at 21.5 MHz and 25 °C) [58]. 
Transverse relaxation rates (R2obs) of the obtained 
samples’ suspensions were measured at 21.5 MHz (0.5 
T) and 25 °C using a Stelar Spinmaster spectrometer 
(Stelar srl, Italy), the normalized (to mM of Fe(III) 
ions) transverse relaxivities (r2) were calculated then 
by subtracting the diamagnetic contribution of pure 
water from these values and dividing by the sample 
concentration. 
Longitudinal and transverse relaxivity were also 
measured at 300 MHz (7 T), with a Bruker Avance 300 
spectrometer (Bruker Biospin, Germany) equipped 
with a Micro 2.5 microimaging probe. The samples 
were transferred into glass capillaries and inserted 
into an agar phantom. T1 and T2 relaxation times were 
then measured. T1 measurement was performed with 
a Multi Slice Multi Echo (MSME) sequence varying 
the repetition time from 50 to 8000 ms (Echo Time 
(TE)/ Repetition Time (TR)/ Number of Averages 
(NAV) 3.74/50-8000/10, Matrix 128x128). T2 
measurement of the samples was performed with a 
MSME sequence varying the echo time from 14 to 280 
ms (TE/TR/NR 14-280/2000/1, Matrix 256x256). 
Sedimentation measurements 
Mobility of the obtained capsules in an external 
non-uniform magnetic field was measured by 
photosedimentometry [47]. The rate of capsules’ 
sedimentation induced by a permanent neodymium 
magnet (340 mT) was measured using the previously 
described setup [57]. The suspension of capsules in 
water was poured in the transparent cuvette, and 660 
nm semiconductor laser beam was placed in parallel 
to the air/water interface. The magnet was applied to 
the cuvette’s wall, so the magnetic field (326 mT at the 
cuvette’s wall) was directed perpendicularly to the 




laser path. Thus, the time dependencies of the capsule 
suspension transparency under permanent magnet 
were obtained. 
Cellular experiments 
Cells and Culture Conditions 
Murine macrophage (RAW 264.7) and mammary 
adenocarcinoma (TS/A) cell lines were used in 
experiments. RAW 264.7 cells were purchased from 
American Type Culture Collection (ATCC LGC 
Standards, Sesto San Giovanni, Italy) and cultured in 
DMEM supplemented with 10% (v/v) of FBS, 2 mM 
L-glutamine, 100 U/mL penicillin and 100 μg/mL 
streptomycin at 37 °C in a humidified atmosphere 
with 5% CO2. TS/A cells, derived from a spontaneous 
BALB/c mammary tumor, were cultured in 
RPMI-1640 supplemented with 10% (v/v) of FBS, 2 
mM L-glutamine, 100 U/mL penicillin and 100 
μg/mL streptomycin at 37 °C in a humidified 
atmosphere with 5% CO2 [59]. 
In vitro MRI 
MRI of macrophages after their incubation with 
the obtained magnetic polyelectrolyte capsules was 
carried out in order to check their ability to be labelled 
with the proposed system. To this purpose, 1x106 
RAW 264.7 cells were seeded into 60 mm Petri dishes. 
The day after the cells were incubated for 2 hours with 
MNP-doped capsules (samples S, C1S, C2S, C6S) at the 
concentration of 9x107 capsules/mL in 2 mL of 
medium. The numbers of cells in suspensions, as well 
as the number of capsules in the samples, were 
counted using a hemocytometer. Incubation with 
medium was used as control. At the end of the 
incubation, cells were profusely washed to remove 
unbound particles, detached by scraping, 
resuspended in 10 mL of PBS and centrifuged twice at 
1100 rpm for 5 min. Further, the cells were 
resuspended in 50 µL of PBS, transferred into glass 
capillaries and centrifuged at 700 rpm for 10 min to 
obtain a cell pellet. The capillaries were then inserted 
into an agar phantom and imaged at 300 MHz (7 T) 
with a Bruker Avance 300 spectrometer (Bruker 
Biospin, Germany) equipped with a Micro 2.5 
microimaging probe. T1 weighted (T1w) Multi Slice 
Multi Echo MSME (Echo Time (TE)/ Repetition Time 
(TR)/ Number of Averages (NAV) 3.7/200/24, Matrix 
128x128) and T2w RARE (TE/Effective TE/TR/NAV/ 
Rare Factor (RF) 3.9/31/4000/6/16, Matrix 128x128) 
sequences were acquired with an axial geometry (3 
slices, slice thickness 0.7 mm). 
The same experiment was performed for selected 
samples on breast cancer TS/A cells in order to 
simulate the process of capsules’ uptake in tumor. For 
this purpose, 1x106 TS/A cells were seeded into 60 
mm Petri dishes. The day after the cells were 
incubated overnight (20 hours) or for 1 hour (the 
timeframe of magnet application planned for in vivo 
experiments) with MNP-doped capsules (samples C1S 
and C6S) at the concentration of 9x107 capsules/mL in 
2 mL of medium. At the end of the incubation, cells 
were also washed out from the unbound particles, 
detached with trypsin/EDTA, resuspended in 10 mL 
PBS and centrifuged twice at 1100 rpm for 5 min. The 
following procedure was the same as described above 
for RAW 264.7 cells. 
Immediately after imaging, the cell pellets (both 
RAW 264.7 and TS/A) were recollected, resuspended 
in 200 µl of PBS and sonicated in ice with a Bandelin 
Sonopuls UW2070 probe sonicator (Bandelin, 
Germany) at 20 W for 30 s. The protein concentration 
in each sample was then measured 
spectrophotometrically using the Bradford protein 
assay and Jenway 6715 UV–Vis spectrophotometer 
(Jenway, USA). To quantify the amount of iron in each 
sample, cell extracts were digested with concentrated 
HNO3 (70% w/w, 1 mL) under microwave heating 
using a MicroSYNTH labstation (Milestone, Italy), 
recollected and analyzed by ICP-MS (Element-2, 
Thermo-Finnigan, Italy). The mean Fe(III) content per 
mg of protein was then calculated for each sample. 
Cytotoxicity 
Cytotoxicity measurements were performed for 
RAW 264.7 cell line to estimate the influence of the 
obtained MNP-doped capsules on the healthy cells. 
For the quantification of live and necrotic cells after 
their incubation with capsules’ suspension, 2x105 cells 
were placed on the 60-mm Petri dish and incubated 
overnight. Then a different number of MNP-doped 
carriers (9, 45, and 90x106 capsules) in 2 mL of growth 
medium was added to cells and incubated for 2 hours 
to simulate the conditions of capsule injection in the 
bloodstream. The largest number of capsules (90x106) 
added to cells was chosen the same as injected further 
to an average mouse (weighing 20 g) in vivo. The 
positive control contained RAW 264.7 cells without 
any additional treatment, the negative control was 
prepared by adding 30% v/v of ethanol to the 
macrophages. The cells of all the groups were 
detached then and stained with 0.125 μg/mL Acridine 
orange (AO) and 15 μg/mL Propidium iodide (PI) for 
15 min. Finally, the macrophages were triple washed 
with PBS and measured using an imaging flow 
cytometer Amnis Mk II (Luminex, USA). 
The analysis of the obtained data was performed 
using the IDEAS software (Luminex, USA). PI-only 
positive cells were recognized as necrotic ones. 
AO-positive and double-positive cells were 
determined as viable cells, where double-positive 




staining was caused by the adsorption of nucleic acids 
from the surrounded dead cells and their debris on 
the surface of the viable ones. The data on RAW 264.7 
cell viability after their incubation with MNP-doped 
capsules were represented as “mean ± standard 
deviations” (n = 5). The one-way analysis of variance 
(ANOVA) was used to determine the statistical 
significance of differences in the obtained values. 
Calculations were made with Microsoft Excel 
software. 
In vivo experiments 
Tumor animal model 
The animal study was approved by the Italian 
Ministry of Health, the following procedures were in 
accordance with institutional guidelines and ensured 
the humane care of the animals. The mice (aged 8 
weeks and weighting 18-22 g) were obtained from the 
animal facility at the Molecular Biotechnology Center 
of the University of Turin. A xenograft breast tumor 
mouse model was prepared by subcutaneous injection 
of 2.5x105 adenocarcinoma TS/A tumor cells into the 
flank of BALB/c female mice. Ten days after tumor 
implantation, when tumor size reached a diameter of 
3-6 mm, the animals were enrolled in the in vivo 
imaging studies. 
MRI experiments 
MRI in vivo experiments were performed at 40 
MHz (1 T) with an Aspect M2 High-Performance MRI 
System (Aspect Magnet Technologies Ltd, Israel) 
consisting of a NdFeB magnet, equipped with a 
solenoid Tx/Tr coil of 35 mm inner diameter. This 
system was equipped with fast gradient coils 
(gradient strength of 450 mT m−1 at 60 A, ramp time of 
250 μs at 160 V) with a field homogeneity of 0.2-0.5 
gauss. Before MRI experiments, the animals were 
anesthetized by intramuscular injection of tiletamine–
zolazepam (Zoletil 100; Virbac, Milan, Italy) 20 mg 
kg−1 and xylazine (Rompun; Bayer, Milan, Italy) 
5 mg kg−1. 
The suspension of magnetic polyelectrolyte 
capsules was diluted in HEPES/NaCl buffer (to 
obtain a suspension 280 mOsm, pH 7.4) and injected 
into the tail vein. The mice underwent MRI before and 
at different time points (1, 4.5, 24 and 48 hours) after 
the capsule injection. A standard T2 Fast Spin Echo 
sequence was used with the following parameters: 
TR/TE/NEX 2500/49/4, resolution of 250 μm, slice 
thickness of 1.5 mm. 
Image analysis and statistics were performed 
using Image J free software. The mean signal intensity 
(SI) values were calculated on a region of interest 
(ROI). The measured SI was normalized to a 
water-containing reference tube to take into account 
the differences in the absolute signal intensity values 
(SIn, where n means “normalized”) among different 
images obtained after mouse repositioning in the MRI 
scanners. The normalization was carried out by 
dividing the SI values of the ROI drawn on the organ 
of interest to the SI values of the ROI drawn inside the 





The mean percent of signal change (SC) was 
calculated according to the following equation: 
𝑆𝐶= 𝑆𝐼𝑛 𝑝𝑜𝑠𝑡−𝑆𝐼𝑛 𝑝𝑟𝑒
𝑆𝐼𝑛 𝑝𝑟𝑒
× 100% (4) 
where SIn pre - the mean signal intensity of the organ of 
interest before the capsule injection, SI post - the mean 
signal intensity of the organ of interest after the 
capsule injection. 
The data were calculated from six independent 
experiments, unless otherwise stated, and expressed 
as the “mean ± SE”. ANOVA and the t-test were 
performed to determine the statistical significance of 
differences in SE in tumor between different time 
points for the same experimental group (p < 0.05) and 
between different experimental groups (p < 0.01). 
Magnetic targeting 
Active magnetic addressing of MNP-doped 
capsules was performed by the application of a 
permanent magnet with a concentrator (0.5 T) to the 
tumor. First, the magnet was placed on the tumor, and 
then the contrast agent was injected into the tail vein 
(Figure 1). The magnet was kept applied to the tumor 




Figure 1. Schematic illustration of the magnetic targeting for MNP-doped capsules. 





Figure 2. Scheme representing the structure of the obtained magnetic polyelectrolyte capsules: sample S containing magnetic nanoparticles (MNPs) in the capsules’ shell and 
samples CnS containing MNPs in both, the shell and the inner volume of the capsules (n is the number of MNPs loading cycles). All the sample types contain poly-arginine (PA) 
and dextran sulfate (DS) polymers in their shell. 
 
Histology 
For ex-vivo histological studies, tumor, liver and 
spleen were excised at different time points post 
injection and fixed overnight in a 10% NBF, 
dehydrated and embedded into paraffin. Then tissue 
slices (5 µm of thickness) were cut with a microtome. 
The presence and localization of iron was investigated 
by means of Perls' Prussian blue staining. Briefly, 
sections were hydrated, covered with equal parts 
mixture of 5% potassium ferrocyanide and 5% HCl for 
1 hour, washed in distilled water and counterstained 
with NFR for 10 minutes. Finally, sections were 
dehydrated, cleared, mounted and examined under 
an Olympus BX14 microscope (Olympus, USA). 
Results and Discussion 
In vitro characterization of magnetic 
polyelectrolyte capsules 
Layer-by-layer (LbL) assembled polyelectrolyte 
capsules represent a unique tool to fabricate micron- 
and submicron-sized theranostic systems which are 
capable of targeted delivery and controlled in-situ 
release [41, 60–64]. So far, effective encapsulation of 
different drugs, including anticancer [65–68], 
RNA/DNA [69–71], growth factors [72, 73], antigens 
[74–76], and other bioactive substances [77–81] was 
demonstrated by means of polyelectrolyte capsules. 
Various multifunctional imaging agents were 
successfully fabricated using LbL technique as well 
[82–84]. Embedding of magnetite nanoparticles into 
the structure of polyelectrolyte capsules opens up the 
perspective for their application in MRI [44, 85–88] as 
well as for improving drug delivery and controlled 
drug release [27, 41, 42, 44].  
Considering this, magnetic nanoparticle 
(MNP)-doped polyelectrolyte capsules of different 
structure were formed and tested for capability of 
their delivery to tumor and MRI-visualization. 
To start with, the colloid of MNPs was 
synthesized by the chemical precipitation method in 
an inert atmosphere [89, 90]. A TEM image of the 
obtained nanoparticles is presented in Figure SM1 
(Supplementary Material, SM). The image 
demonstrates a spherical shape of MNPs with an 
average size of 5.0 ± 0.9 nm. DLS measurements show 
a particle hydrodynamic diameter of 8.8 ± 2.0 nm 
(Figure SM1 in Supplementary Material). 
Magnetic polyelectrolyte capsules were then 
formed using this MNP suspension. Different capsule 
structures were formulated in order to determine a 
balanced carrier composition in terms of magnetic 
and MRI contrast properties. To accomplish this, 
MNPs were embedded either into the capsules’ shell 
(sample S) or into both, the shell and the inner volume 
of the capsules (samples CnS, where n is the number 
of MNPs loading cycles). The scheme representing the 
structure of the obtained capsules is provided in 
Figure 2. The iron content in the obtained capsules 
(determined as Fe(III)) depending on their structure is 
presented in Table 1. 
Biodegradability is a crucial property of drug 
delivery systems. For micron- and submicron-sized 
capsule formulation, the biodegradable polymers, 




either synthetic or natural, are often used since they 
are capable of being split into biocompatible products 
by chemical or enzyme-catalyzed hydrolysis [91]. 
Poly-L-arginine (PA) and dextran sulfate (DS) have 
been widely employed to design polyelectrolyte 
capsules that were found to be biocompatible and 
degradable both in vitro and in vivo [92, 93]. Thus, here 
the MNP-doped capsules were fabricated using these 
polymers by LbL technique. SEM images of the 
obtained carriers are presented in Figure 3. The 
average size of the capsules was 0.8 ± 0.1 μm. 
The SEM images clearly demonstrated that the 
morphology of the capsules’ surface differed 
depending on the amount of incorporated magnetite. 
In particular, sample S containing MNPs only in 
polyelectrolyte shell represented thin submicron 
capsules with quite smooth surface (Figure 3 a, e). 
Embedding of MNPs into the inner volume of the 
capsules resulted in increased wall thickness (Figure 3 
b-d and f-h). Moreover, the higher magnetite content 
was in capsules, the rougher and thicker they 
appeared. 
According to our previous data [46], the 
concentration of MNPs adsorbed at the shell defines 
MRI contrast properties of polyelectrolyte capsules. 
Specifically, the MR contrast for both T1 and T2 was 
shown to depend on the distance between magnetite 
nanoparticles in the capsules’ shell. With the larger 
distance between MNPs in the shell layer, relaxation 
rate increases resulting in MR signal enhancement. In 
the current study, the amount of magnetite in a shell 
was chosen to provide the best MRI contrast [46]. 
However, the polyelectrolyte carriers containing 
MNPs only in their shell possessed low sensitivity to 
magnetic field due to insufficient magnetite 
concentration [47]. Meanwhile, the embedding of 
higher amount of MNPs into the structure of 
polyelectrolyte capsules can open up the possibilities 
for their navigation with external magnetic field [42, 
44, 94, 95]. 
The opportunity to improve the magnetic 
navigation property of polyelectrolyte capsules by the 
incorporation of MNPs into their inner volume was 
studied here. The effect of changing the amount of 
incorporated magnetite on the mobility of the 
obtained capsules in an external magnetic field was 
measured by means of photosedimentometry. The 
results are represented in Figure 4. The graphs 
demonstrate the change in transmission of the capsule 
suspensions under the application of a magnet 
depending on the capsules’ structure. The 
photographs of the capsule suspensions in cuvette 
before and after the magnet application are presented 
in Figure SM2 in Supplementary Material. 
 
Table 1. Structure and characteristics of the magnetic polyelectrolyte capsules at 0.5 Т and 25°C 
Sample Structure [Fe3+] mM r1 (mM×s)-1 r2 (mM×s)-1 r2/r1 
S (PA/DS/PA/MNPs/PA/DS) 0.43 19.7 92.1 4.7 
C1S (MNPs)/(PA/DS/PA/MNPs/PA/DS) 4.4 17.8 79.3 4.5 
C2S (MNPs)2/(PA/DS/PA/MNPs/PA/DS) 8.8 5.3 23.4 4.4 
C6S (MNPs)6/(PA/DS/PA/MNPs/PA/DS) 15.8 0.6 1.5 2.7 
 
 
Figure 3. SEM images of magnetic polyelectrolyte capsules: (a, e) - sample S; (b, f) – sample C1S; (c, g) – sample C2S; (d, h) - sample C6S performed at different magnifications. 





Figure 4. Photosedimentometry of magnetic polyelectrolyte capsules S, C1S, C2S and 
C6S dispersed in water during the time represented as time dependence of the 
suspension transparence in an external magnetic field. 
 
Figure 5. T1w (a) and T2w (b) magnetic resonance images acquired at 7 T of glass 
capillaries containing RAW 264.7 cells incubated for 2 hours in the absence (control 
cells, CTRL) and in the presence of magnetic polyelectrolyte capsules (samples S, C1S, 
C2S, C6S). (c) Histogram representing the amount of iron added to (yellow columns) 
and entrapped by (green columns) RAW 264.7 cells after the 2-hours incubation with 
samples S, C1S, C2S, and C6S represented as moles of iron per 1 mg of cellular 
proteins; the calculations were based on ICP-MS analysis of Fe(III) content and 
spectrophotometric evaluation of proteins by means of Bradford assay. 
 
According to the obtained data, the sample C6S 
was the most sensitive to an external non-uniform 
magnetic field. However, it possessed the lowest r1 
and r2 relaxivities at 21.5 MHz (0.5 T) (Table 1). In 
contrast, the sample S without magnetite in the inner 
volume revealed as the best T2 contrast agent among 
all studied carriers with an r2/r1 ratio of 4.7. The 
T1-NMRD profile for this sample (at 25 and 37°C) is 
shown in Figure SM3, and it is characterized by a 
broad hump centered at around 10 MHz. It should be 
noted that the obtained profile appears very similar to 
Endorem™, a dextran-coated iron oxide NPs 
formulation formerly approved for clinical MRI, and 
to other iron-oxide loaded nanosystems [53,96], thus 
suggesting similar relaxometric properties for these 
magnetic systems. 
A decreasing tendency was observed at 21.5 
MHz (Table 1, Figure SM4) for both r1 and r2 
relaxivities with the enhancement of magnetite 
content inside the capsule, with r2 values displaying a 
sharper decay. A similar trend has been previously 
reported for magnetic polymer micro- and submicron 
capsules [88, 97], where it was ascribed to the effect of 
clustering and inhomogeneous spatial distribution of 
the embedded MNPs within the capsules on the 
dipolar magnetic energy and on the water 
protons/MNP interaction. Interestingly, despite these 
r1 and r2 decays, their ratio (r2/r1) remained almost the 
same with increasing loading cycles up to 2 (samples 
S, C1S and C2S). Meanwhile, with the more drastic 
increase of magnetite content inside the capsule, as for 
the C6S sample, the possibility of MNP aggregation 
raised, leading to a significant r2/r1 decrease (see 
Table 1). 
As far as the proposed contrast agent is 
capsule-based and the amount of MNPs inside these 
capsules differed depending on the sample structure, 
it was useful to compare also the relaxivities of the 
samples S and C6S normalizing them to the capsules’ 
concentration (indicated as r1caps and r2caps) instead of 
concentration of Fe(III) ions. Such comparison 
demonstrated no drastic difference between the 
obtained r1caps values (9.3 vs 9.9 (pM×s)-1 for the S and 
C6S samples, respectively). However, the transverse 
relaxivity r2caps for the sample S was still higher than 
for the sample C6S (43 vs 26 (pM×s)-1, respectively). 
Before carrying out the in vivo study, the 
possibility to generate a sufficient MRI contrast was 
assessed for the RAW 264.7 cells labeled with the 
synthesized magnetic polyelectrolyte capsules. This 
murine phagocytic cell line was used as an immune 
cell model simulating capsules’ uptake [98]. T1 and 
T2-weighted MR images were acquired at 7 T on 
cellular pellets obtained upon 2-hours incubation with 
MNP-doped capsules (samples S, C1S, C2S, C6S). In 
order to study the effect of the sample structure, the 
concentration of capsules added to cells was set at the 
same level for all the samples, while the total amount 
of incubated iron differed. The resulting T1- and 
T2-weighted MR images are presented in Figure 5 (a, 
b). 
The MNP-doped polyelectrolyte capsules 
demonstrated the ability to be entrapped by 
macrophages generating sufficient MRI contrast in 
both T1 and T2 weighted images. The R1obs and R2obs 
relaxation rates were not measurable for the samples 
C1S, C2S and C6S due to the extremely high Fe(III) 
content. High iron concentration resulted in a strong 
T2 effect, affecting also T1w contrast as decreasing T1 
signal intensity. While for the sample S, where the 




magnetite content was significantly lower, the T1 and 
T2 signal was much higher than for CnS ones. Thus, 
the r1 and r2 relaxivities (at 7 T and normalized to 
Fe(III) ions) were calculated just for the cells 
incubated with sample S and corresponded to 11.5 
and 711.5 mM-1s-1, respectively. It should be noted 
that R1obs and R2obs values were more than 100 and 5 
times higher than the relaxation rates measured for 
the control RAW 264.7 cells (incubated without 
capsules), respectively (29.6 vs 0.3 s-1 for R1obs; 92.7 vs 
20.6 for R2obs). The relaxivities of the magnetic 
polyelectrolyte capsules acquired at 7 T are provided 
in Table SM1 (Supplementary Material). 
The amount of iron entrapped by cells after their 
incubation with capsules was evaluated by ICP-MS. 
The mean Fe(III) content per mg of cellular protein for 
each sample was then calculated based on these data 
and presented in Figure 5c. These results 
demonstrated a good labeling ability in vitro 
rendering the proposed capsules-based contrast agent 
promising for in vivo MRI application. According to 
spectrophotometric evaluation of proteins with a 
Bradford assay, 1 mg of proteins was equal to 106 
RAW cells. 
High amount of iron was entrapped also when 
the MNP-doped capsules were incubated with 
adenocarcinoma TS/A cells simulating the process of 
capsules’ uptake in targeted tumor tissues (see Figure 
SM5 in SM). The drastic changes in MR properties of 
these tumor cells resulting from the internalization of 
the capsules were noted as well (Figure SM5 in SM). 
Accordingly, one might expect to observe the steep 
decrease of MR signal in tumor as soon as the 
proposed theranostic system is successfully delivered 
there. 
Cytotoxicity of the obtained capsules was also 
determined prior to the start of in vivo experiments. 
For this purpose, MNP-doped capsules of various 
concentrations were incubated with RAW 264.7 cells. 
For cytotoxicity assay, the largest number of capsules 
added to a dish of cells was 9x107 (45x106 
capsules/mL of medium), as it corresponded to the 
number of capsules further administered to an 
average mouse (weighing 20 g) in vivo. The results are 
presented in Figure 6. 
The study of macrophages viability under the 
2-hour incubation with magnetic polyelectrolyte 
capsules of various structure performed using double 
AO-PI staining demonstrated a good 
cytocompatibility of the samples added even at the 
highest concentration of 450 capsules per cell (9x107 
capsules per dish). Although cell viability slightly 
varied with the capsules’ structure and concentration, 
it was no less than 76% for the C6S sample (Figure 6, 
a). For a better illustration, a scatter plots showing the 
distribution of double stained AO-PI RAW 264.7 cells 
for the highest concentration of S and C6S samples 
were provided (Figure 6 b). As far as the viability was 
higher than 70% for all the samples, the carriers were 
considered non-cytotoxic in accordance with ISO 
10993-5:2009 [99]. According to ANOVA-test, the 
change in capsule’s structure for the same capsule 
concentration did not lead to any statistically 
significant differences in RAW 264.7 cell viability. The 
change in carrier concentration caused statistically 
significant difference only for S and C1S samples, 
while for the others the differences were not 
statistically significant even if the average values were 
noticeably lower. 
Based on the data obtained, the capsules with 
MNPs incorporated only into their shells (sample S) 
were selected as the best T2 contrast agent in terms of 
MRI visualization properties in vitro. Meanwhile, the 
capsules containing the highest amount of magnetite 
(MNPs in the shell and inner 
volume of the capsules, 
sample C6S) revealed as the 
optimal system concerning 
the highest sensitivity to a 
magnetic field and possibility 
to generate a sufficient 
negative MRI contrast upon 
the cellular internalization. 
At the same time, both 
samples applied even at a 
high concentration did not 
cause a prominent cytotoxic 
effect. By this means, the 
samples S and C6S were 




Figure 6. (a) Cytotoxicity of magnetic polyelectrolyte capsules S, C1S, C2S and C6S. The statistically significant differences 
calculated by ANOVA-test are represented as * (p<0.05) and ** (p<0.01). (b) Flow cytometry scatter plot for Acridine 
orange/Propidium Iodide double stained RAW 264.7 cells after capsules’ uptake. Negative control represents cells without 
capsules after induced necrotic death; positive control represents cells without any additional treatment. 




Magnetic polyelectrolyte capsules in grafted 
breast tumor mouse model 
The possibility to deliver the obtained magnetic 
polyelectrolyte capsules to a tumor was then studied 
by means of in vivo MRI. To be effective, the proposed 
theranostic system needs to provide a good balance 
between MR contrast and magnetic navigation 
properties when applied in vivo as we aimed at 
successful magnetic targeting realization. 
TS/A cells were used to form a grafted tumor 
model in mice. It is well known that high permeability 
of the tumor vasculature compared to normal tissue 
allows large molecules and small particles to enter the 
tumor interstitial space and the compromised 
lymphatic filtration allows them to stay there (EPR 
effect) [100]. As far as the permeabilized vasculature 
varies from 200 to 800 nm, such passive targeting 
effect is expected to take place for the proposed 
delivery system as well. That should result in 
intratumor accumulation of the capsules and, thus, in 
MR contrast enhancement. Assuming this possible 
effect, the control experiments on MNP-doped 
capsules’ injection not followed by external magnet 
application (so-called “no magnet”) were performed 
to estimate the real effect of magnetic targeting. 
The sample S was tested first as providing better 
T2 contrast properties. 4 nmol Fe(III)/g (4.5x106 
capsules/g body weight) were administered to mice 
(n=6) by intravenous injection. The accumulation in 
tumor, liver and spleen tissues was assessed 1, 4.5, 24 
and 48 h after the injection by acquiring MR images at 
1 T and calculating T2 contrast. The contrast was 
expressed as the “percent of T2 signal change” 
representing the percentage change in the mean signal 
intensity of the organ of interest in comparison to 
pre-injection images (see Material and Methods). The 
results are shown in Figure 7 (a). 
Injection of sample S provided generation of a 
marked MRI contrast in vivo. The maximum of T2 
signal decrease in tumor (-18 ± 4 %) was registered 1 
hour after the injection, meaning that the amount of 
the MNP-doped capsules in tumor was maximal at 
this time point. The systemic clearance of not 
internalized capsules led to a sufficient decrease in T2 
signal intensity in liver and spleen as well (-39 ± 4 % 
and -19 ± 4 %, respectively). 
 
 
Figure 7. Sample S. Percent of T2 signal change in the organs of interest (tumor, liver and spleen) at different time points resulting from the systemic injection of sample S: (a) 
without and (b) with the application of the external magnet to the tumor, an asterisk (*) indicates significant differences in T2 signal change in tumor in comparison to pre-injection 
images; (c) comparison of T2 signal change in the mice tumors with and without magnet application. The values correspond to the “mean ± SE”, n=6 per each group (no magnet/ 
with magnet). (d) Representative T2-weighted axial MR images of mice acquired before (pre) and 1 hour after the injection. Tumors are marked with blue circles and presented 
in pseudo colors; a water-containing reference tube is presented in both, original grayscale and pseudo colors. 




In order to improve the tumor accumulation of 
the proposed submicron capsule-based MR probe, 
magnetic targeting was applied then. To accomplish 
this, a permanent magnet with a concentrator (0.5 T) 
was placed on the tumor right before the injection of 
capsules (Figure 1, Materials and Methods) and kept 
applied for 1 hour further. MR images were acquired 
again at 1 T and T2 contrast was measured. The 
obtained results are presented in Figure 7 (b). The 
comparison of the mean T2 signal change in the mice 
tumors with and without magnet application is 
presented in Figure 7 (c, d). 
The maximum of T2 signal decrease in tumor 
was again reached 1 h after the injection. However, no 
significant difference was observed between the 
groups of mice measured with and without the 
external magnet application, neither 1 hour after the 
injection (-15 ± 5 % and -18 ± 4 %, respectively), nor at 
the later time points (Figure 7c). Quantification of the 
T2 signal in liver and spleen did not show any 
significant impact of the magnet application as well. 
Meanwhile, the axial MR images of mice (Figure 7d) 
demonstrated the absence of signal artefacts in tumor 
after the application of the magnet that presumably 
resulted from a more homogeneous distribution of the 
magnetic particles. By this means, the exposure to a 
magnetic field may allow the overcoming of the 
impaired drugs/nanosystems’ distribution often 
observed in tumors due to disordered vasculature, 
hypoxic microenvironments and elevated interstitial 
fluid pressure [40,101]. 
As mentioned above, the MR contrast 
enhancement in the tumor indicates a successful 
targeting of the contrast agent. Thus, polyelectrolyte 
capsules with MNPs incorporated into their shells 
(sample S), which played a role of such agent here 
providing almost 20% T2 signal change, appeared to 
be a promising delivery system. Once co-loaded with 
an anticancer drug, these capsules may contribute to 
its accumulation in tumor tissue. Furthermore, 
gradual fading of T2 contrast within 48 hours in both 
spleen (approaching the pre-injection values) and 
liver (recovering to half of the pre values) took place 
in our study (Figure 7 a, b). That pointed at a 
relatively short period of capsules’ elimination 
allowing for repeated administrations in anticancer 
therapy. Realization of magnetic targeting of 
polyelectrolyte capsules to the tumor, which has 
failed for sample S due to its low sensitivity to 
external magnetic field, might enhance the amount of 
a delivered drug as well. However, the more sensitive 
magnetic system should be used for this purpose. 
Thus, in the second set of experiments, in vivo 
MRI was carried out in mice receiving sample C6S as it 
demonstrated the highest sensitivity to a magnetic 
field in vitro. Here, 147 nmol Fe(III)/g were 
intravenously administered to mice (n=4) maintaining 
the same capsules’ concentration used for the sample 
S (4.5x106 capsules/g body weight). The T2 contrast in 
tumor, liver and spleen tissues was assessed again 1, 
4.5, 24 and 48 h after the injection by acquiring MR 
images at 1 T and the resulting data are shown in 
Figure 8. 
Injection of the sample C6S resulted in a 
significant T2 signal decrease (in comparison to pre 
injection values) in tumors of both mice groups, 
exposed or not to the external magnetic field (Figure 8 
a, b). However, no enhancement in MRI contrast was 
observed in tumor if compared to the treatment with 
sample S, while the mean T2 signal in liver and spleen 
decreased drastically. Such an effect is caused by the 
dense packing of MNPs in the inner volume of the C6S 
capsules. As described above, a high amount of 
magnetite inside the capsule negatively affects the T2 
contrast properties of the sample (Table 1). Enhanced 
local concentration of MNPs promotes a strong 
“quenching” effect on the observed relaxivity of intact 
capsules [46,102]. That resulted in a less accentuated 
T2 signal decrease in tumor for the sample C6S as 
compared with sample S. Meanwhile, upon the 
degradation of MNP-doped capsules, liberation of 
magnetite particles together with the enhancement of 
interparticle distance take place causing a sufficient 
change in MR contrast of the reticuloendothelial 
system (RES)-associated organs [46]. Here, it resulted 
in such a drastic decrease of T2 signal in liver and 
spleen after the injection of sample C6S in comparison 
to sample S, especially 48 hours post injection. 
Specifically, in liver the mean T2 signal change values 
obtained at this time point for sample C6S exceeded 
the ones obtained for sample S by 3 times. In spleen a 
more than 10-times higher T2 signal decrease and 
thus, T2 contrast enhancement, was registered 48 
hours after the injection of sample C6S (compared 
again to treatment with sample S). 
Nevertheless, the main effect associated with the 
injection of highly loaded polyelectrolyte/magnetite 
capsules (sample C6S) occurs when comparing their 
injection with and without an external magnetic field 
application (Figure 8 c, d). The capsules have 
demonstrated a good magnetic sensitivity in vivo 
providing a significantly stronger (p < 0.01) T2 
contrast 1 hour after the injection in tumor exposed to 
magnet (-12 ± 2 % vs -4 ± 2 % T2 signal change for mice 
treated and not treated with magnet, respectively). At 
the same time, significantly lower (p < 0.05) T2 
contrast was observed in spleen of the treated with 
magnet mice (T2 signal change was -43 ± 7 %, while 
for untreated mice it corresponded to -65 ± 5 %). Both 
facts pointed at successful magnetically guided 




targeting of the sample C6S to tumor. 
In order to validate this effect of external magnet 
application and to verify that MNP-doped capsules 
were indeed delivered to tumor tissue, mice were 
sacrificed after the last MRI acquisition (48 hours after 
the injection of sample C6S) to carry out histological 
analysis of their liver, spleen and tumor. The Perls’ 
(Prussian Blue) staining protocol was used to assess 
localization of the capsules and iron deposits in 
tissues. The results are presented in Figure 9. 
 
 
Figure 8. Sample C6S. Percent of T2 signal change in the organs of interest (tumor, liver and spleen) at different time points resulting from the systemic injection of sample C6S: 
(a) without and (b) with the application of the external magnet to the tumor, an asterisk (*) indicates significant differences in T2 signal change in tumor in comparison to 
pre-injection images; (c) comparison of T2 signal change in the mice tumors with and without magnet application, two asterisks (**) indicate significant difference (p < 0.01) 
between these two groups. The values correspond to the “mean ± SE”, n=4 per each group (no magnet/ with magnet). (d) Representative T2-weighted axial MR images of mice 
acquired before (pre) and 1 hour after the injection. Tumors are marked with blue circles and presented in pseudo colors; a water-containing reference tube is presented in both, 
original grayscale and pseudo colors. 
 
Figure 9. Perls’ staining of representative mice tissues 48 hours after the injection of sample C6S without (a-c) and with (d-f) the application of an external magnet: (a, d) – liver; 
(b, e) – spleen; (c, f) – tumor. Black arrows indicate iron deposits in tumor. Scale bars, 100 µm. 
 






The Perls’ staining positivity of histological 
sections is shown for all the investigated organs 
indicating the presence of iron deposits 48 hours after 
the sample injection (Figure 9), that well matched the 
MRI results (Figure 8 a-c). No marked difference 
between the groups with and without magnet 
application was found for liver (Figure 9 a, d) and 
spleen (Figure 9 b, e) tissues, where the iron was 
located almost exclusively in macrophages. In tumor, 
instead, even if the amount of residual contrast agent 
by this time was limited for both groups, the 
arrangement of MNP-doped capsules/iron deposits 
differed significantly (Figure 9 c, f). That clearly 
shows that an hour-long application of external 
magnet to tumor following the intravenous injection 
of the magnetically sensitive capsules resulted in a 
denser and clustered positioning of the capsules in 
tumor tissue, as the formed aggregates remained 
there even 47 hours after removing the magnetic field. 
By this means, the obtained results indicated a 
successful realization of the magnetic targeting using 
the proposed MNP-doped polyelectrolyte capsules 
that might guarantee the delivery of a fairly higher 
amount (at least 3 times, relying on T2 contrast 
observed) of a co-loaded drug into the tumor under 
external magnetic field. Such enhanced targeted 
delivery of polyelectrolyte capsules offers great 
perspectives for drug delivery improvement. 
Conclusions 
In summary, the current study highlighted the 
strategy of magnetic biodegradable polyelectrolyte 
carriers’ design to develop an efficient delivery 
system combining the externally controlled 
navigation and MRI visualization properties. The 
effect of changing the structure of 
polyelectrolyte/magnetite submicron capsules and 
the amount of incorporated magnetite has been 
studied systematically moving from in vitro to in vivo. 
Incorporation of magnetite nanoparticles into the 
inner volume of capsules in addition to their shell 
labeling significantly improved the magnetic 
targeting ability. Intravenous injection of the most 
highly loaded sample containing 2.94 μmol Fe(III) to 
mice with a breast cancer model under external 
magnet application resulted in a three-fold 
enhancement in T2 MRI contrast in tumor (compared 
to the tumor untreated with magnet) together with a 
pronounced contrast lowering in spleen. Such 
findings rendered the proposed magnetic capsules 
effective in terms of both external magnetic 
field-guided targeting of tumors and MRI monitoring. 
Summation of these properties of the polyelectrolyte 
capsules with biocompatibility and the ability of 
co-loading with an anticancer drug holds the prospect 
for the effective theranostic platform development 
aiming at improved anticancer therapy. Further 
research should be aimed at the application of 
external physical stimuli (light, ultrasound or 
alternating magnetic field) providing controlled 
in-situ drug release or synergetic therapeutic effect in 
tumor. 
Supplementary Material  
Supplementary figures and tables. 
http://www.ntno.org/v05p0362s1.pdf  
Acknowledgements 
The work was supported by the European 
Commission within Marie Curie Actions 
"International Research Staff Exchange Scheme" 
(IRSES-GA-2013-612673). Preparation of magnetic 
polyelectrolyte capsules, SEM and sedimentation 
measurements, in vitro cytotoxicity evaluation, as well 
as in vivo data analysis including quantification of the 
mean MR signal change, were supported by the 
Russian Science Foundation (project no 19-73-10123). 
The authors acknowledge the Italian Ministry of 
Research for FOE contribution to the 
Euro-BioImaging MultiModal Molecular Imaging 
Italian Node (www.mmmi.unito.it). The authors 
acknowledge the Open Lab of Advanced Microscopy 
(OLMA) at the Molecular Biotechnology Center 
(MBC) for support. The authors would like to thank 
Mr Vsevolod S. Atkin for the SEM measurements, Mr 
Maxwell A. Astle for the TEM measurements and Mr 
Alexey V. Ermakov for the help with graphical 
illustrations. 
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1.  Mishra DK, Shandilya R, Mishra PK. Lipid based nanocarriers: a translational 
perspective. Nanomedicine: NBM. 2018; 14: 2023–50.  
2.  Sreekanth V, Bajaj A. Recent Advances in Engineering of Lipid Drug 
Conjugates for Cancer Therapy. ACS Biomater Sci Eng. 2019; 5: 4148–66.  
3.  Molavi F, Barzegar-Jalali M, Hamishehkar H. Polyester based polymeric nano 
and microparticles for pharmaceutical purposes: A review on formulation 
approaches. J Control Release. 2020; 320: 265–82.  
4.  De Cock LJ, De Koker S, De Geest BG, et al. Polymeric Multilayer Capsules in 
Drug Delivery. Angew Chemie Int Ed. 2010; 49: 6954–73.  
5.  Cai A, Zhu Y, Qi C. Biodegradable Inorganic Nanostructured Biomaterials for 
Drug Delivery. Adv Mater Interfaces. 2020; 7: 2000819.  
6.  Manzano M, Vallet‐Regí M. Mesoporous Silica Nanoparticles for Drug 
Delivery. Adv Funct Mater. 2020; 30: 1902634.  
7.  Zhou J, Yu G, Huang F. Supramolecular chemotherapy based on host–guest 
molecular recognition: a novel strategy in the battle against cancer with a 
bright future. Chem Soc Rev. 2017; 46: 7021–53.  
8.  Peng L, Liu S, Feng A, Yuan J. Polymeric Nanocarriers Based on Cyclodextrins 
for Drug Delivery: Host–Guest Interaction as Stimuli Responsive Linker. Mol 
Pharm. 2017; 14: 2475–86.  
9.  Busatto S, Walker SA, Grayson W, et al. Lipoprotein-based drug delivery. Adv 
Drug Deliv Rev. 2020; 159: 377–90.  




10.  Thaxton CS, Rink JS, Naha PC, Cormode DP. Lipoproteins and lipoprotein 
mimetics for imaging and drug delivery. Adv Drug Deliv Rev. 2016; 106: 116–
31.  
11.  Sawyer AJ, Kyriakides TR. Matricellular proteins in drug delivery: 
Therapeutic targets, active agents, and therapeutic localization. Adv Drug 
Deliv Rev. 2016; 97: 56–68.  
12.  Farooq MA, Aquib M, Ghayas S, et al. Whey protein: A functional and 
promising material for drug delivery systems recent developments and future 
prospects. Polym Adv Technol. 2019; 30: 2183–91.  
13.  Dissanayake S, Denny WA, Gamage S, Sarojini V. Recent developments in 
anticancer drug delivery using cell penetrating and tumor targeting peptides. J 
Control Release. 2017; 250: 62–76.  
14.  Song Z, Chen X, You X, et al. Self-assembly of peptide amphiphiles for drug 
delivery: the role of peptide primary and secondary structures. Biomater Sci. 
2017; 5: 2369–80.  
15.  Chung YH, Cai H, Steinmetz NF. Viral nanoparticles for drug delivery, 
imaging, immunotherapy, and theranostic applications. Adv Drug Deliv Rev. 
2020; 156: 214–35.  
16.  Alemzadeh E, Dehshahri A, Izadpanah K, Ahmadi F. Plant virus 
nanoparticles: Novel and robust nanocarriers for drug delivery and imaging. 
Colloids Surfaces B Biointerfaces. 2018; 167: 20–7.  
17.  Kudela P, Koller VJ, Lubitz W. Bacterial ghosts (BGs)—Advanced antigen and 
drug delivery system. Vaccine. 2010; 28: 5760–7.  
18.  Cao Z, Liu J. Bacteria and bacterial derivatives as drug carriers for cancer 
therapy. J Control Release. 2020; 326: 396–407.  
19.  Yoo J-W, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and 
biomimetic drug delivery carriers. Nat Rev Drug Discov. 2011; 10: 521–35.  
20.  Villa CH, Anselmo AC, Mitragotri S, Muzykantov V. Red blood cells: 
Supercarriers for drugs, biologicals, and nanoparticles and inspiration for 
advanced delivery systems. Adv Drug Deliv Rev. 2016; 106: 88–103.  
21.  Walker S, Busatto S, Pham A, et al. Extracellular vesicle-based drug delivery 
systems for cancer treatment. Theranostics. 2019; 9: 8001–17.  
22.  El-Sawy HS, Al-Abd AM, Ahmed TA, El-Say KM, Torchilin VP. 
Stimuli-Responsive Nano-Architecture Drug-Delivery Systems to Solid Tumor 
Micromilieu: Past, Present, and Future Perspectives. ACS Nano. 2018; 12: 
10636–64.  
23.  Sun T, Dasgupta A, Zhao Z, Nurunnabi M, Mitragotri S. Physical triggering 
strategies for drug delivery. Adv Drug Deliv Rev. 2020; 158: 36-62. 
24.  Pacardo DB, Ligler FS, Gu Z. Programmable nanomedicine: synergistic and 
sequential drug delivery systems. Nanoscale. 2015; 7: 3381–91.  
25.  Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for 
drug delivery. Nat Rev Drug Discov. 2014; 13: 813–27.  
26.  Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, 
therapy and theranostics. Theranostics. 2020; 10: 4557–88.  
27.  Zhu D, Roy S, Liu Z, Weller H, Parak WJ, Feliu N. Remotely controlled 
opening of delivery vehicles and release of cargo by external triggers. Adv 
Drug Deliv Rev. 2019; 138: 117–32.  
28.  Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to 
tumours. Nat Rev Mater. 2016; 1: 16014.  
29.  Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges 
towards targeted delivery of cancer therapeutics. Nat Commun. 2018; 9: 1410.  
30.  Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming 
biological barriers to drug delivery. Nat Biotechnol. 2015; 33: 941–51.  
31.  Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting Strategies for Tissue-Specific 
Drug Delivery. Cell. 2020; 181: 151–67.  
32.  Srinivasarao M, Low PS. Ligand-Targeted Drug Delivery. Chem Rev. 2017; 
117: 12133–64.  
33.  Lakshmanan S, Gupta GK, Avci P, et al. Physical energy for drug delivery; 
poration, concentration and activation. Adv Drug Deliv Rev. 2014; 71: 98–114.  
34.  Jang D, Jeong J, Song H, Chung SK. Targeted drug delivery technology using 
untethered microrobots: a review. J Micromechanics Microengineering. 2019; 
29: 053002.  
35.  Polyak B, Friedman G. Magnetic targeting for site-specific drug delivery: 
applications and clinical potential. Expert Opin Drug Deliv. 2009; 6: 53–70.  
36.  Liu Y-L, Chen D, Shang P, Yin D-C. A review of magnet systems for targeted 
drug delivery. J Control Release. 2019; 302: 90–104.  
37.  Price PM, Mahmoud WE, Al-Ghamdi AA, Bronstein LM. Magnetic Drug 
Delivery: Where the Field Is Going. Front Chem. 2018; 6: 619.  
38.  Tietze R, Zaloga J, Unterweger H, et al. Magnetic nanoparticle-based drug 
delivery for cancer therapy. Biochem Biophys Res Commun. 2015; 468: 463–70.  
39.  Shapiro B, Kulkarni S, Nacev A, Muro S, Stepanov PY, Weinberg IN. Open 
challenges in magnetic drug targeting. Wiley Interdiscip Rev Nanomedicine 
Nanobiotechnology. 2015; 7: 446–57.  
40.  Mody V V., Cox A, Shah S, Singh A, Bevins W, Parihar H. Magnetic 
nanoparticle drug delivery systems for targeting tumor. Appl Nanosci. 2014; 4: 
385–92.  
41.  Antipina MN, Sukhorukov GB. Remote control over guidance and release 
properties of composite polyelectrolyte based capsules. Adv Drug Deliv Rev. 
2011; 63: 716–29.  
42.  Voronin D V., Sindeeva OA, Kurochkin MA, et al. In Vitro and in Vivo 
Visualization and Trapping of Fluorescent Magnetic Microcapsules in a 
Bloodstream. ACS Appl Mater Interfaces. 2017; 9: 6885–93.  
43.  Mayorova OA, Sindeeva OA, Lomova M V., et al. Endovascular addressing 
improves the effectiveness of magnetic targeting of drug carrier. Comparison 
with the conventional administration method. Nanomedicine: NBM. 2020; 28: 
102184.  
44.  Novoselova M V., German S V., Sindeeva OA, et al. Submicron-Sized 
Nanocomposite Magnetic-Sensitive Carriers: Controllable Organ Distribution 
and Biological Effects. Polymers (Basel). 2019; 11: 1082.  
45.  Anani T, Rahmati S, Sultana N, David AE. MRI-traceable theranostic 
nanoparticles for targeted cancer treatment. Theranostics. 2021; 11: 579–601.  
46.  German S V., Bratashov DN, Navolokin NA, et al. In vitro and in vivo MRI 
visualization of nanocomposite biodegradable microcapsules with tunable 
contrast. Phys Chem Chem Phys. 2016; 18: 32238–46.  
47.  Kozlova, German, Atkin, et al. Magnetic Composite Submicron Carriers with 
Structure-Dependent MRI Contrast. Inorganics. 2020; 8: 11.  
48.  Golovin YI, Gribanovsky SL, Golovin DY, et al. Towards nanomedicines of the 
future: Remote magneto-mechanical actuation of nanomedicines by 
alternating magnetic fields. J Control Release. 2015; 219: 43–60.  
49.  Kobayashi T. Cancer hyperthermia using magnetic nanoparticles. Biotechnol J. 
2011; 6: 1342–7.  
50.  Hergt R, Dutz S, Müller R, Zeisberger M. Magnetic particle hyperthermia: 
nanoparticle magnetism and materials development for cancer therapy. J Phys 
Condens Matter. 2006; 18: S2919–34.  
51.  Moros M, Idiago-López J, Asín L, et al. Triggering antitumoural drug release 
and gene expression by magnetic hyperthermia. Adv Drug Deliv Rev. 2019; 
138: 326–43.  
52.  Liu JF, Jang B, Issadore D, Tsourkas A. Use of magnetic fields and 
nanoparticles to trigger drug release and improve tumor targeting. Wiley 
Interdiscip Rev Nanomedicine Nanobiotechnology. 2019; 11: e1571.  
53.  Ruggiero MR, Crich SG, Sieni E, et al. Magnetic hyperthermia efficiency and 1 
H-NMR relaxation properties of iron oxide/paclitaxel-loaded PLGA 
nanoparticles. Nanotechnology. 2016; 27: 285104.  
54.  Dunne M, Epp-Ducharme B, Sofias AM, Regenold M, Dubins DN, Allen C. 
Heat-activated drug delivery increases tumor accumulation of synergistic 
chemotherapies. J Control Release. 2019; 308: 197–208.  
55.  Donath E, Sukhorukov GB, Caruso F, Davis SA, Möhwald H. Novel Hollow 
Polymer Shells by Colloid-Templated Assembly of Polyelectrolytes. Angew 
Chemie Int Ed. 1998; 37: 2201–5.  
56.  Parakhonskiy B V., Haase A, Antolini R. Sub-Micrometer Vaterite Containers: 
Synthesis, Substance Loading, and Release. Angew Chemie. 2012; 124: 1221–3.  
57.  German S V., Novoselova M V., Bratashov DN, et al. High-efficiency 
freezing-induced loading of inorganic nanoparticles and proteins into micron- 
and submicron-sized porous particles. Sci Rep. 2018; 8: 17763.  
58.  Vaccaro M, Mangiapia G, Paduano L, et al. Structural and Relaxometric 
Characterization of Peptide Aggregates Containing Gadolinium Complexes as 
Potential Selective Contrast Agents in MRI. ChemPhysChem. 2007; 8: 2526–38.  
59.  Nanni P, De Giovanni C, Lollini P-L, Nicoletti G, Prodi G. TS/A: a new 
metastasizing cell line from a BALB/c spontaneous mammary 
adenocarcinoma. Clin Exp Metastasis. 1983; 1: 373–80.  
60.  Xiong R, Soenen SJ, Braeckmans K, Skirtach AG. Towards Theranostic 
Multicompartment Microcapsules: in-situ Diagnostics and Laser-induced 
Treatment. Theranostics. 2013; 3: 141–51.  
61.  Zhao S, Caruso F, Dähne L, et al. The Future of Layer-by-Layer Assembly: A 
Tribute to ACS Nano Associate Editor Helmuth Möhwald. ACS Nano. 2019; 
13: 6151–69.  
62.  Wuytens P, Parakhonskiy B, Yashchenok A, Winterhalter M, Skirtach A. 
Pharmacological aspects of release from microcapsules — from polymeric 
multilayers to lipid membranes. Curr Opin Pharmacol. 2014; 18: 129–40.  
63.  Volodkin D, Skirtach A, Möhwald H. Bioapplications of light-sensitive 
polymer films and capsules assembled using the layer-by-layer technique. 
Polym Int. 2012; 61: 673–9.  
64.  De Geest BG, Sanders NN, Sukhorukov GB, Demeester J, De Smedt SC. 
Release mechanisms for polyelectrolyte capsules. Chem Soc Rev. 2007; 36: 
636–49.  
65.  Campbell J, Kastania G, Volodkin D. Encapsulation of Low-Molecular-Weight 
Drugs into Polymer Multilayer Capsules Templated on Vaterite CaCO3 
Crystals. Micromachines. 2020; 11: 717.  
66.  Ermakov A V., Verkhovskii RA, Babushkina I V., et al. In Vitro Bioeffects of 
Polyelectrolyte Multilayer Microcapsules Post-Loaded with Water-Soluble 
Cationic Photosensitizer. Pharmaceutics. 2020; 12: 610.  
67.  Trushina DB, Akasov RA, Khovankina A V., Borodina TN, Bukreeva T V., 
Markvicheva EA. Doxorubicin-loaded biodegradable capsules: Temperature 
induced shrinking and study of cytotoxicity in vitro. J Mol Liq. 2019; 284: 215–
24.  
68.  Sharma V, Vijay J, Ganesh MR, Sundaramurthy A. Multilayer capsules 
encapsulating nimbin and doxorubicin for cancer chemo-photothermal 
therapy. Int J Pharm. 2020; 582: 119350.  
69.  Jewell C, Lynn D. Multilayered polyelectrolyte assemblies as platforms for the 
delivery of DNA and other nucleic acid-based therapeutics. Adv Drug Deliv 
Rev. 2008; 60: 979–99.  
70.  Borodina TN, Markvicheva EA, Kunizhev S, Möhwald H, Sukhorukov GB, 
Kreft O. Controlled Release of DNA from Self-Degrading Microcapsules. 
Macromol Rapid Commun. 2007; 28: 1894–9.  
71.  Tarakanchikova Y, Alzubi J, Pennucci V, et al. Biodegradable Nanocarriers 
Resembling Extracellular Vesicles Deliver Genetic Material with the Highest 
Efficiency to Various Cell Types. Small. 2020; 16: 1904880.  
72.  Tong W, Gao C. Multilayer Microcapsules with Tailored Structures and 
Properties as Delivery Carriers for Drugs and Growth Factors. In: Polymeric 




Biomaterials for Tissue Regeneration. Singapore: Springer Singapore;. 2016; p: 
75–99.  
73.  She Z, Wang C, Li J, Sukhorukov GB, Antipina MN. Encapsulation of Basic 
Fibroblast Growth Factor by Polyelectrolyte Multilayer Microcapsules and Its 
Controlled Release for Enhancing Cell Proliferation. Biomacromolecules. 2012; 
13: 2174–80.  
74.  De Geest BG, Willart MA, Hammad H, et al. Polymeric Multilayer 
Capsule-Mediated Vaccination Induces Protective Immunity Against Cancer 
and Viral Infection. ACS Nano. 2012; 6: 2136–49.  
75.  De Geest BG, Willart MA, Lambrecht BN, et al. Surface-Engineered 
Polyelectrolyte Multilayer Capsules: Synthetic Vaccines Mimicking Microbial 
Structure and Function. Angew Chemie Int Ed. 2012; 51: 3862–6.  
76.  Chiu Y-C, Gammon JM, Andorko JI, Tostanoski LH, Jewell CM. Assembly and 
Immunological Processing of Polyelectrolyte Multilayers Composed of 
Antigens and Adjuvants. ACS Appl Mater Interfaces. 2016; 8: 18722–31.  
77.  Yanina IY, Svenskaya YI, Prikhozhdenko ES, et al. Optical monitoring of 
adipose tissue destruction under encapsulated lipase action. J Biophotonics. 
2018; 11: e201800058.  
78.  Lomova M V., Sukhorukov GB, Antipina MN. Antioxidant Coating of 
Micronsize Droplets for Prevention of Lipid Peroxidation in Oil-in-Water 
Emulsion. ACS Appl Mater Interfaces. 2010; 2: 3669–76.  
79.  De Koker S, De Cock LJ, Rivera-Gil P, et al. Polymeric multilayer capsules 
delivering biotherapeutics. Adv Drug Deliv Rev. 2011; 63: 748–61.  
80.  Andreeva DV. Polyelectrolyte multilayers for drug delivery. In: Advances and 
Avenues in the Development of Novel Carriers for Bioactives and Biological 
Agents. Elsevier. 2020; p: 183–209.  
81.  Van der Meeren L, Li J, Konrad M, Skirtach AG, Volodkin D, Parakhonskiy B 
V. Temperature Window for Encapsulation of an Enzyme into Thermally 
Shrunk, CaCO 3 Templated Polyelectrolyte Multilayer Capsules. Macromol 
Biosci. 2020; 20: 2000081.  
82.  Van der Meeren L, Li J, Parakhonskiy B V., Krysko D V., Skirtach AG. 
Classification of analytics, sensorics, and bioanalytics with polyelectrolyte 
multilayer capsules. Anal Bioanal Chem. 2020; 412: 5015–29.  
83.  Barrefelt ÅA, Brismar TB, Egri G, et al. Multimodality imaging using 
SPECT/CT and MRI and ligand functionalized 99mTc-labeled magnetic 
microbubbles. EJNMMI Res. 2013; 3: 12.  
84.  Ahmed M, Gustafsson B, Aldi S, et al. Molecular Imaging of a New 
Multimodal Microbubble for Adhesion Molecule Targeting. Cell Mol Bioeng. 
2019; 12: 15–32.  
85.  Yi Q, Li D, Lin B, et al. Magnetic Resonance Imaging for Monitoring of 
Magnetic Polyelectrolyte Capsule In Vivo Delivery. Bionanoscience. 2014; 4: 
59–70.  
86.  Kozlova AA, German S V, Novoselova M V, et al. Polyelectrolyte Parg/DS 
submicrocapsules functionalized by magnetite nanoparticles as effective MR 
contrast agents. J Phys Conf Ser. 2018; 1092: 012067.  
87.  Alford A, Rich M, Kozlovskaya V, et al. Ultrasound-Triggered Delivery of 
Anticancer Therapeutics from MRI-Visible Multilayer Microcapsules. Adv 
Ther. 2018; 1: 1800051.  
88.  Grillo R, Gallo J, Stroppa DG, et al. Sub-Micrometer Magnetic 
Nanocomposites: Insights into the Effect of Magnetic Nanoparticles 
Interactions on the Optimization of SAR and MRI Performance. ACS Appl 
Mater Interfaces. 2016; 8: 25777–87.  
89.  Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic 
media. IEEE Trans Magn. 1981; 17: 1247–8.  
90.  German S V., Inozemtseva OA, Markin A V., Metvalli K, Khomutov GB, Gorin 
DA. Synthesis of magnetite hydrosols in inert atmosphere. Colloid J. 2013; 75: 
483–6.  
91.  Jain JP, Yenet Ayen W, Domb AJ, Kumar N. Biodegradable Polymers in Drug 
Delivery. In: Biodegradable Polymers in Clinical Use and Clinical 
Development. Hoboken, NJ, USA: John Wiley & Sons, Inc. 2011; p: 1–58.  
92.  De Koker S, De Geest BG, Cuvelier C, et al. In vivo Cellular Uptake, 
Degradation, and Biocompatibility of Polyelectrolyte Microcapsules. Adv 
Funct Mater. 2007; 17: 3754–63.  
93.  De Geest BG, Vandenbroucke RE, Guenther AM, et al. Intracellularly 
Degradable Polyelectrolyte Microcapsules. Adv Mater. 2006; 18: 1005–9.  
94.  Valdepérez D, del Pino P, Sánchez L, Parak WJ, Pelaz B. Highly active 
antibody-modified magnetic polyelectrolyte capsules. J Colloid Interface Sci. 
2016; 474: 1–8.  
95.  Vidiasheva I V., Abalymov AA, Kurochkin MA, et al. Transfer of cells with 
uptaken nanocomposite, magnetite-nanoparticle functionalized capsules with 
electromagnetic tweezers. Biomater Sci. 2018; 6: 2219–29.  
96.  Laurent S, Forge D, Port M, et al. Magnetic Iron Oxide Nanoparticles: 
Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, 
and Biological Applications. Chem Rev. 2008; 108: 2064–110.  
97.  Abbasi AZ, Gutiérrez L, del Mercato LL, et al. Magnetic Capsules for NMR 
Imaging: Effect of Magnetic Nanoparticles Spatial Distribution and 
Aggregation. J Phys Chem C. 2011; 115: 6257–64.  
98.  Feng Q, Liu Y, Huang J, Chen K, Huang J, Xiao K. Uptake, distribution, 
clearance, and toxicity of iron oxide nanoparticles with different sizes and 
coatings. Sci Rep. 2018; 8: 2082.  
99.  ISO 10993-5 Biological evaluation of medical devices - Part 5: Tests for in vitro 
cytotoxicity in vitro cytotoxicity. International Organization for 
Standardization Geneva.  2009.  
100.  Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. 
Adv Drug Deliv Rev. 2011; 63: 131–5.  
101.  Shojaee P, Niroomand-Oscuii H, Sefidgar M, Alinezhad L. Effect of 
nanoparticle size, magnetic intensity, and tumor distance on the distribution 
of the magnetic nanoparticles in a heterogeneous tumor microenvironment. J 
Magn Magn Mater. 2020; 498: 166089.  
102.  Baroni S, Ruggiero MR, Bitonto V, et al. In vivo assessment of tumour 
associated macrophages in murine melanoma obtained by low-field 
relaxometry in the presence of iron oxide particles. Biomaterials. 2020; 236: 
119805. 
